Abstract-Cardiac hypertrophy is characterized by increased myofibrillogenesis. Angiotensin II (Ang-II) is an essential mediator of the pressure overload-induced cardiac hypertrophy in part through RhoA/ROCK (small GTPase/Rhoassociated coiled-coil containing protein kinase) pathway. FHOD3 (formin homology 2 domain containing 3), a cardiac-restricted member of diaphanous-related formins, is crucial in regulating myofibrillogenesis in cardiomyocytes. FHOD3 maintains inactive through autoinhibition by an intramolecular interaction between its C-and N-terminal domains. Phosphorylation of the 3 highly conserved residues (1406S, 1412S, and 1416T) within the C terminus (CT) of FHOD3 by ROCK1 is sufficient for its activation. However, it is unclear whether ROCK-mediated FHOD3 activation plays a role in the pathogenesis of Ang-II-induced cardiac hypertrophy. In this study, we detected increases in FHOD3 expression and phosphorylation in cardiomyocytes from Ang-II-induced rat cardiac hypertrophy models. 
C ardiac hypertrophy (CH) is initially an adaptive growth response to an increased pressure overload and neurohormonal activation, such as conditions seen in patients with aortic stenosis and hypertension. [1] [2] [3] If the overload sustains, CH can progress and ultimately deteriorate into heart failure and sudden death. Anatomically, CH is featured with a thickened ventricular wall and narrowed ventricular cavity. At the cellular level, CH is characterized by an increase in cardiomyocyte size filled with the exaggerated formation of myofibrils. 2, 3 At the molecular level, CH shows increased expressions of immediate-early genes (c-fos, c-jun, c-myc, etc), activations of the fetal genes (atrial natriuretic peptide [ANP] , skeletal α-actin, β-myosin heavy chain [β-MHC], etc), and increases in protein synthesis. 2, 3 Angiotensin II (Ang-II) is a critical factor in mediating CH. [4] [5] [6] In cultured neonatal rat cardiomyocytes (NRCs), Ang-II treatment is sufficient to generate CH phenotype. [3] [4] [5] [6] [7] Multiple signaling pathways have been shown to be involved in mediating Ang-II-induced CH. Among those, activation of the G-protein-coupled Ang-II type-1 receptor (AT1R) signaling is the most important mechanism. 8, 9 Ang-II/AT1R activates Ca translocation; Ang-II/AT1R activates transforming growth factor-β expression and increases SRF-mediated gene expression; Ang-II/AT1R activates MAP (mitogen-activated protein) kinases (ERK1/2 [extracellular regulating kinase], JNK [c-Jun N-terminal kinase], and p38MAPK), receptor tyrosine kinases (PDGF, EGFR, insulin receptor, etc), and nonreceptor tyrosine kinases (JAK/STAT, Src, focal adhesion kinase, etc). [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] All these Ang-II/AT1R-activated pathways are known to be involved in the pathogenesis of CH.
Ang-II/AT1R also induces CH through activation of small GTPase (RhoA) and its downstream ROCK (Rho-associated coiled-coil containing protein kinase) pathway. It has been previously reported that inhibition of RhoA/ROCK activities could suppress Ang-II-induced CH. [18] [19] [20] [21] [22] [23] There are 2 ROCK isoforms, ROCK1 and ROCK2, that share overall 65% homology at the amino acid level 24 and have similar tissue distributions. 25 Although many studies have suggested that ROCK1 may play critical roles in leukocyte, 26 macrophage, 27 and stem cells, 28 whereas ROCK2 may play essential roles in endothelial cells, 29 cardiomyocytes, 30 and smooth muscle cells, 31, 32 mechanisms responsible for tissue-specific functions of each ROCK isoform are far from clear. RhoA/ROCK not only controls stress fiber (SF) formation in nonmuscle cells, but also mediates the assembly of premyofibrils in cardiomyocytes. 18, 19 Premyofibrils, which have similar morphology to the SFs in nonmuscle cells by phalloidin staining, are nonstriated actin fibers composed of nonmuscle myosin IIB and sarcomeric proteins, such as α-actinin, tropomyosin, and troponin. The process involving actin assembly to form premyofibrils and mature into myofibrils is termed myofibrillogenesis. Myofibrillogenesis is metabolically important for maintaining normal myofibril structure. Increased myofibrillogenesis in terminally differentiated cardiomyocytes is a major feature of Ang-II/AT1R-induced CH. [18] [19] [20] [21] [22] [23] However, the signaling mechanism of Ang-II-induced myofibrillogenesis in cardiomyocytes remains undetermined.
Recent identified FHOD3 (formin homology 2 domain containing 3) is a skeletal and cardiac-specific member of diaphanous-related formin family proteins. 33 It shares structural similarities to its nonmuscle homolog FHOD1, [34] [35] [36] [37] with a diaphanous inhibitory domain in the N terminus, FH1 and FH2 in the middle, and diaphanous autoregulatory domain (DAD) in the CT. [38] [39] [40] [41] [42] [43] FHOD3 is implicated to play a role in myofibrillogenesis in cardiomyocytes from studies using both in vitro cell culture and in vivo animal models. Depletion of FHOD3 in cultured cardiomyocytes has been reported to disrupt sarcomere organization. 38 FHOD3 null mice showed embryonic lethality in E11.5 because of the failure of premyofibrils maturation and myocardial development. 43 Similar to FHOD1, FHOD3 exists in an autoinhibited state in cells by intramolecular interaction between its diaphanous inhibitory domain and DAD domains and thus masking its functional FH1 and FH2 domains. FHOD3 also has 3 highly conserved residues (1406S, 1412S, and 1416T) within its DAD ( Figure 1A) . 39 It has been reported that phosphorylation of these 3 residues by ROCK1 releases FHOD3 autoinhibition, leading to FH1/FH2-mediated activation of actin fibers synthesis, a critical step for myofibrillogenesis. 39, 44 Recent reports from Iskratsch et al, 39 Wooten et al, 40 and Kan-o et al 41 have shown that the expression of FHOD3 in the cardiac tissue was reduced in patients with dilated cardiomyopathy (DCM) and was increased in patients with hypertrophied cardiomyopathy (HCM). Furthermore, Arimura et al 42 reported that an FHOD3 Y1249N mutation interferes actin fiber assembly that leads to DCM. These evidence indicates that FHOD3 might be a key regulator for CH.
However, it still remains to be determined whether FHOD3 activation by ROCK1 plays a role in the pathogenesis of Ang-II-induced CH. In the present report, we show that Ang-II infusion remarkably upregulates and activates FHOD3 in a rat CH model. In cultured cardiomyocytes, ROCK inhibitor attenuates Ang-II-induced upregulation and activation of FHOD3 and cell hypertrophy. We identified that FHOD3 is mainly phosphorylated by ROCK2 at 1412S and 1416T residues. Adenoviral expression of a phosphor-mimetic FHOD3 mutant in cultured cardiomyocytes mimics Ang-IIinduced myofibrillogenesis and cell hypertrophy, whereas a phosphor-resistant mutant abolished all myofibrillogenesis. Cotransfection of FHOD3 with constitutively active ROCK2 significantly increases much more SF formation than with constitutively active ROCK1. ROCK2 knocked down in NRCs, but not ROCK1, shows a blunted increment in cell size in response to Ang-II. Together, we establish a direct role of FHOD3 activation by ROCK2 in Ang-II-induced CH.
Materials and Methods

Antibodies and Reagents
FHOD3 phosphor antibodies against FHOD3 1406pS, 1412pS, and 1416pT were produced in rabbits (4 rabbits for each) using synthetic peptides PRERKR(pS)RANRKSL, RSRANRK(pS)LRRTLKS, and RKSLRR(pT)LKSGLT (Boyun, China) as immunogen, respectively. In each case, an N-terminal cysteine was added to the synthetic peptides to facilitate coupling. Crude sera were purified using respective phosphopeptide-conjugated affinity columns, and the bound fractions were further filtered with a column conjugated with a corresponding unphosphorylated peptide, PRERKRSRANRKSL, RSRANRKSLRRTLKS, or RKSLRRTLKSGLT. The flow-through fractions were phosphor-specific FHOD3 antibodies: anti-1406pS, anti-1412pS, and anti-1416pT antibodies.
After antibodies were purchased, normal mouse IgG (sc-2025; Santa Cruz, CA), normal rabbit IgG (sc-2027; Santa Cruz), rabbit polyclonal anti-FHOD3 (M-102; Santa Cruz), anti-FHOD3-CT (AV46342, Sigma-Aldrich), anti-α-actinin (EA-53; Abcam), anti-ROCK1 (611136; BD), anti-ROCK2 (610623; BD), anti-ROCK1 (C8F7; Cell Signaling), anti-myosin phosphatase 1 (MYPT1; 2634; Cell Signaling), antiphospho-MYPT1-Thr853 (4563; Cell Signaling), anti-6His (Aogma Biotech), anti-M2 (Sigma-Aldrich), horseradish peroxidase-conjugated anti-GAPDH (AP0063; Bioworld Tech), and TRITC (tetraethyl rhodamine isothiocyanate)-linked secondary antibodies (Jackson Laboratories). Y27632, Ang-II, active ROCK1 (Ac-ROCK1; R1281), and active ROCK2 (Ac-ROCK1; R1156) were purchased from Sigma-Aldrich, PKG (cGMP-dependent protein kinase) Iα from Promega, and [γ- 
Molecular Cloning
Full-length (FL) human FHOD3 cDNA (GenBank: NM_025135) was purchased from OriGene (Rockville, MD). The FL cDNA and its ΔN (412-1439) were cloned into the pEGFP-C1 (green fluorescent protein; Clontech), 2-411 and 412-843 into the pET28a (Novagen) and pCMVTag-2 (Stratagene), 1323-1439 and 1376-1439 into pGEX-4T-1 (GE Healthcare), and 1376-1439 into pCI (Promega). Using wild-type (WT) GFP-FL-FHOD3 and GST-FHOD3-1376-1439 vector as templates, serial single-, double-, or triple-point mutants replacing the 3 residues (1406S, 1412S, and 1416T) with phosphor-mimetic aspartate or phosphor-resistant alanine were made by site-directed mutagenesis.
Constitutively active ROCK1/2-1080 (CA-ROCK1) and ROCK2/2-1114 (CA-ROCK2) fragments were amplified from FL human ROCK1 and ROCK2 cDNAs (kindly provided by Surks from Tufts Medical School) by polymerase chain reaction (PCR) and subcloned into pECFP-C1 (cyan fluorescent protein; modified from pEGFP-C1). 31 All primers used are listed in Tables S1 and S2 in the online-only Data Supplement. All obtained constructs were verified by sequencing.
GST-and 6His-Fusion Protein Expression, Purification, and Pull-Down Assay
All GST-and 6His-fusion proteins were expressed in BL-21 cells by induction of isopropyl-β-D-thiogalactopyranoside and purified through glutathione-sepharose beads (G4510; Sigma-Aldrich) or Ni beads (Cat-70666; Qiagen). 6His-fusion proteins were eluted from Ni beads with 250 mmol/L imidazole (Sigma-Aldrich) followed by dialysis in the NTN buffer (500 mmol/L NaCl, 20 mmol/L Tris-HCl, 0.5% NP-40, pH 7.5) at 4°C.
Fifty microliters of glutathione-sepharose beads coupled with GSTfusion proteins were mixed with 2 μg of purified 6His-tagged protein in 600 μL TNNEG buffer (20 mmol/L Tris-HCl, 150 mmol/L NaCl, 0.1% Nonidet P-40, 0.5 mol/L EDTA (ethylene diamine tetraacetic acid), 5% glycerol, 0.01 μg/mL each of aprotinin, leupeptin, and pepstatin A, 2 mmol/L phenylmethylsulfonyl fluoride, pH 7.5) for 2 hours at 4°C, followed by washing 4× using the same buffer. The beads were then boiled in SDS sample buffer. The bound proteins were resolved by SDS-PAGE and immunoblotted with indicated antibodies. 
Rat CH Model
This study was approved by the Ethics Committee of Xinhua Hospital. All animal experiments were performed in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals.
Rat CH model was generated by inducing rat with continuous infusion of Ang-II (0.7 mg kg −1 d −1 ) through a subcutaneously implanted osmotic minipump (Alzet model 2ML4, DURECT Co), as described previously. 45 In brief, male Sprague Dawley rats at 7 weeks of age (180-200 g; SLAC Animal, China) were anesthetized with sodium pentobarbital (50 mg/kg IP). The minipumps were primed overnight according to the manufacturer's instruction and loaded with saline (n=10) or Ang-II (n=16) dissolved in sterile solution (0.9% NaCl and 0.01 N acetic acid). Half of the rats with Ang-II infusion (n=8) were further intragastrically administrated with Valsartan (20 mg/kg daily; Novartis, Switzerland) for 4 weeks together with the implantation. 46 Rat blood pressures were measured before and after infusion of Ang-II using a sphygmomanometer for rodent (BP2010A; Softron, Japan). Four weeks after treatment, the rat hearts were harvested, weighted, snap-frozen in liquid nitrogen.
Isolation and Culture of NRCs
To isolate NRCs, the rat ventricles were excised from 2-day-old Sprague Dawley rats, rinsed in ice-cold saline, minced into pieces smaller than 1 mm 3 , and incubated overnight at 4°C in D-Hanks balanced salt solution containing 0.5% trypsin. The small pieces were then collected and further digested with type-II collagenase (100 U/ mL; Worthington) for 40 minutes at 37°C. The digestion was terminated by adding Dulbecco's Modified Eagle Medium (DMEM; Gibco-Life) supplemented with 10% fetal bovine serum, and the small pieces were resuspended by pipetting. The resulting cell suspensions were filtered through a cellular sifter (200 mesh), incubated in DMEM with 10% fetal bovine serum for 70 minutes. Cells in suspension were removed, and the remaining cells attached to the bottom were collected, replated at a density of 3-4×10 5 cells/mL, and cultured in DMEM with 10% fetal bovine serum, 100 U/mL penicillin, 100 μg/mL streptomycin, and 0.1 mmol/L bromodeoxyuridine. The purity of the cardiomyocytes isolated using this method was >90%, based on the immunostaining with antibody against α-actinin, a cardiomyocyte marker.
Western Blotting and ROCK Activity Assay
Cardiac tissue or cultured cells were rinsed with cold phosphatebuffered saline (PBS), fixed with 10% trichloroacetic acid (SigmaAldrich) in PBS containing 2 mmol/L EDTA and 10 mmol/L dithiothreitol, collected, and microcentrifuged at 4°C for 10 minutes at 12 000 rpm. The pellets were then washed twice in cold acetone containing 2 mmol/L dithiothreitol and air-dried. 47 Proteins in the pellets were extracted with radioimmunoprecipitation assay lysis buffer (Beyotime, China) containing proteinase inhibitors, followed by homogenization or sonication. 31 The protein concentrations were measured by Bradford assay (Bio-Rad). Samples were further solubilized in SDS sample buffer, separated on 7.5%-10% SDS-PAGE, transferred onto PVDF membranes (polyvinylidene fluoride; Millipore), and blocked in either 5% milk or 1% bovine serum albumin (for phosphor antibodies) for 1 hour. After incubation with primary antibodies, blots were washed 4× in PBS followed by incubation with horseradish peroxidase-conjugated secondary antibodies (1:1000). The blots were visualized using ECL detection kit (Thermo) on the Chemi Doc XRS + (Bio-Rad) and quantified with Image Laboratory 2.0 on the Criterion Stain Free System. ROCK activity in both myocardial tissues and cultured cardiomyocytes was quantified by the ratio of phosphorylated MYPT1 Thr-853 (MYPT1-853pT) and total MYPT1 (t-MYPT1) detected by Western blotting analysis. 48 Cell lysate from cultured cardiac fibroblasts, which were harvested after stimulation with lysophosphatidic acid (2 mmol/L) for 10 minutes, was used as positive control to standardize the results of Western blotting analyses from several membranes.
Reverse Transcription and Real-Time Quantitative PCR
One microgram of total RNA, isolated from rat ventricular tissue or cultured cells using TRIzol (Invitrogen), was reversely transcribed into cDNA using a 5×PrimeScript RT master mix, including PrimeScript RTase, RNase inhibitor, random 6-mers, oligo dT (deoxythymine) primer, dNTP (deoxy-ribonucleoside triphosphate) mixture, and reaction buffer (Takara, Japan). 49 Expressions of β-MHC and ANP genes were quantified by real-time quantitative PCR (ABI 7500 Fast) using the primers listed in Table S3 .
Transient Transfection and Immunoprecipitation
COS-1 cells were transfected with indicated plasmids using Lipofectamine 2000 (Invitrogen) when reached to 50% to 70% confluences. For immunoprecipitation studies, cells were harvested, and the experiments were performed according to a protocol described previously.
47,49
Cloning of Adenoviral Constructs, Adenovirus Packaging, and Transduction in NRCs FL-FHOD3-WT, -AAA, and -DDD were first cloned into the pENTRlRES-GFP vector (Invitrogen). Subsequently, the coding sequence of FHOD3 or its mutants was inserted into the backbone vector of pAd-CMV-V5-DEST (Invitrogen) by homologous recombination. All constructs (pAd/CMV/V5-DEST-FHOD3 and its mutants) were verified by sequencing. The adeno constructs were linearized by Pac I digestion, and DNA fragments were purified and transfected into 293A cells by lipofection. Viral particles were harvested and concentrated (Novobio Scientific Ltd, China).
To make ROCK1-or ROCK2-specific short hairpin RNA (shRNA) adenovirus to silence endogenous ROCK1 or ROCK2, 4 pairs of oligonucleotide shRNAs were synthesized (Table S4) . Each pair was annealed and ligated into pENTR/U6 (Invitrogen). The knockdown efficiency of each shRNAs was validated by real-time quantitative PCR using cDNA obtained by reverse transcription of the total RNA from the COS-1 cells cotransfected with an expression plasmid containing FL FHOD3 cDNA and the corresponding pENR/U6 plasmid encoding the shRNA. Only those shRNAs that significantly reduced FHOD3 expression were transferred into a destination vector pAd/ Block/iT-DEST to generate adenovirus. Further selections were conducted in NRCs by transduction of 2 to 3 kinds of adenovirus.
The adenoviral doses used for transduction in NRCs were based on the multiplicity of infection of cardiomyocyte, which is 50. NRCs, grown on cover glasses at 50%-70% confluence, were incubated with adenovirus for 4 hours before changing to fresh media. The transduction efficiencies were determined by GFP fluorescence 48 hours after transduction.
Histology, Immunofluorescence, and Confocal Microscopy
Cardiac tissue was fixed in 4% paraformaldehyde for 24 hours, embedded in paraffin, and sectioned horizontally in 4 µm and processed for hematoxylin eosin staining. NRCs or COS-1 cells grown on coverslips were fixed with 4% paraformaldehyde, permeabilized in 0.3% Triton X-100, blocked in PBS containing 5% donkey serum (Jackson Laboratory) for 1 hour, and incubated with primary antibodies for 1 hour, followed by extensive washing with PBS and further incubation with TRITC-conjugated secondary antibodies for 1 hour. The cells nuclei were stained for with 1 μg/mL DAPI (4′,6-diamidino-2-phenylindole; Dojindo, Japan), and the slides were mounted with Antifade medium (Molecular Probes, OR). The cell images were captured with LSM510 confocal microscope (Leica, Germany), and the cell surface area was determined with Image-J 1.48v software (National Institutes of Health).
In Vitro Phosphorylation Assay
Recombinant Ac-ROCK1 (5 IU), Ac-ROCK2 (5 IU), or PKGIα (1.5 IU) was mixed with 30 μL of glutathione-sepharose beads coupled with GST-fusion proteins in a phosphorylation assay buffer (50 mmol/L Tris-HCl 10 mmol/L MgCl 2 , 0.5 mmol/L CaCl 2 , 1 mmol/L DTT, 25 mmol/L NaF, 10 mmol/L glycerophosphate, 50 nmol/L okadaic acid, 0.5 mg/mL bovine serum albumin, pH 7.5) and incubated on ice for 30 minutes. A kinase buffer (50 mmol/L Tris-HCl, 5 mmol/L MgCl 2 , pH 7.5) was used for PKGIα. 35 Three μCi [γ-32 P]-ATP was then added to the mixture and incubated at 30°C for 15 minutes. The samples were boiled in SDS sample buffer and subjected to SDS-PAGE followed by an autoradiography. In cold assay for Western blotting, 200 μmol/L ATP (Promega) was used.
Statistical Analysis
The experimental data were expressed as mean±SEM. Differences between multiple groups were compared by 1-way ANOVA followed by Games-Howell post hoc testing, according to the test of homogeneity. P values <0.05 were considered significant (SPSS 18.0 software, Chicago).
Results
FHOD3 Is Activated by Its C-Terminal DAD Phosphorylation
Similar to FHOD1, FHOD3 has a highly conserved positivecharged cluster in its CT, containing 3 phosphorylable residues (1406S, 1412S, and 1416T; Figure 1A) . 35, 37, 39 Also, FHOD3 is reported to be autoinhibited through its N-terminus binding to its CT, 44 which is thought to be the mechanism to maintain FHOD3 in inactive state. However, the functional domains involved in autoinhibition have not been defined. To map the functional domains involved in autoinhibition, we cloned 4 fragments: 2 N-terminal (6His-2-411 and -412-843) and 2 C-terminal fragments (GST-1376-1439 and -1323-1439; Figure 1A ) into bacterial expression vectors. Each His-/GSTtagged truncated protein was purified, and GST pull-down assays were performed. As shown in Figure 1B , both GST-1376-1439 and GST-1323-1439, but not GST alone, specifically bound to 6His-2-411, but not to 6His-412-843. To further validate the interaction between FHOD3 2-411 and 1376-1439 in vivo, 2 expression constructs were created by cloning 2-411 into flag-tagged pCMV-Tag-2 and 1376-1439 into pCI vectors. The expression constructs were transiently expressed in COS-1 cells, and the whole cell lysates were used for immunoprecipitation assays. Anti-M2 and anti-FHOD3 CT antibodies were able to detect 2-411 and 1323-1439, respectively, in both input and immunoprecipitated lanes ( Figure 1B) . These results show that FHOD3 intramolecular autoinhibition is mediated by the interaction between its N terminus 2-411 and CT 1376-1439.
To determine whether the phosphorylation of 3 highly conserved serine/threonine (S/T) residues located within CT 1376-1439 has any effect on regulating FHOD3 activation, we analyzed effects of the phosphor-mutants of these 3 residues on FHOD3 autoinhibition. As shown in Figure 1C , we generated 2 full panels of mutants of GFP-FL-FHOD3 and GST-1376-1439, with the 3 S/T residues serially changed to phosphor-mimetic aspartate or phosphor-resistant alanine. Pull-down assays were performed. Each GST-1376-1439 phosphor-mutants showed different affinities to 6His-2-411. Compared with WT, AAA and SSD mutants showed the strongest binding to 6His-2-411. DST, SDT, and DSD mutants showed moderate, whereas DDT and SDD showed a weaker binding. Remarkably, DDD did not bind to 6His-2-411 ( Figure 1D ). These results confirmed that phosphorylation at S/T residues in DAD domain prevented C-terminal DAD interaction with FHOD3 N-terminal domain. To test whether FHOD3 activation by phosphorylation has any functional consequences, we evaluated these mutants on SF formation in COS-1 cells ( Figure 1E ). N-terminal deletion mutant ΔN (412-1439), which is fully active, was used as a positive control for SF formation. No SF formation was observed when WT or AAA mutant were expressed in COS-1 cells ( Figure 1F ). Phosphor-mimetic mutants DDD expression induced the highest degree of SF formation, similar to ΔN. The expression of DST mutant, on the other hand, induced the least SF formation. These results demonstrate that similar to previous report on FHOD1, 37 FHOD3 activation is regulated by phosphorylation at residues 1412S and 1416T, not at 1406S in the C-terminal domain.
Ang-II Induced CH, Activated and Upregulated FHOD3, and Enhanced ROCK Activities In Vivo, Valsartan Attenuated All These Changes
To elucidate the role of FHOD3 phosphorylation in the pathogenesis of CH, we generated 3 phosphor-specific antibodies against 1406pS, 1412pS, and 1416pT, respectively. The specificities were validated by in vitro phosphorylation assay using Ac-ROCK1, which has been reported to be able to phosphorylate all 3 residues in both FHOD1 36, 37 and FHOD3. 39, 44 Our 1412pS and 1416pT antibodies could specifically recognize Ac-ROCK1-mediated 1412pS and 1416pT, respectively ( Figure S1A ). However, the 1406pS antibodies could not recognize Ac-ROCK1-mediated 1406pS. Previously, we have reported that PKG could phosphorylate 1131S in FHOD1, 35 which is corresponding to the 1406S in FHOD3. We examined whether 1406pS antibodies could specifically recognize PKGIα-mediated 1406pS. As shown in Figure S1B , our 1406pS antibodies showed specificity to PKGIα-mediated 1406S phosphorylation. These results not only validated the specificities of our phosphor antibodies, but also suggested that 1412S and 1416T, but not 1406S, are ROCK1 substrates.
To study the role of FHOD3 phosphorylation in the pathogenesis of CH, we used a rat CH model by infusing Ang-II in Sprague Dawley rats for 4 weeks using a subcutaneous minipump. Compared with the saline-infused Sham rats, rats receiving Ang-II infusion developed significant increases in both systolic and mean blood pressure (Figure 2A ) and significant decreases in heart rates ( Figure S2 ). CH was also observed in the hearts of those rats, with increased heart weight index (3.28±0.09→4.01±0.14; P<0.05; Figure 2B ), enlargement in the size of cardiomyocyte (294±8→463±16 μm 2 ; P<0.01), and increased expression of hypertrophic markers β-MHC (4.95±0.71-fold; Figure 2C ) and ANP (10.20±0.46-fold). We detected a significant increase in both FHOD3 mRNA (5.42±0.69-fold) and protein (3.83±0.77-fold) levels in the left ventricle of CH rats. The phosphorylation at 1412S (3.07±0.85-fold) and 1416T (1.85±0.56-fold) also significantly increased, whereas 1406S exhibited negligible change ( Figure 2D ). Accordingly, ROCK activity, as measured by the ratio of MYPT1-853pT/t-MYPT1, was also increased dramatically (208.6±27.4%; Figure 2E ). Together, these data suggest that upregulation of FHOD3 expression, increased 1412S/1416T phosphorylation, and ROCK activity may play a role in Ang-II-induced CH.
To further explore the link between Ang-II and FHOD3 upregulation and activation, we treated Ang-II-infused rats with Valsartan, an AT1R blocker, to examine whether Valsartan could alleviate the Ang-II-induced FHOD3 upregulation and activation. As expected, intragastrically administrated Valsartan significantly reduced the blood pressures ( Figure 2A ) and the heart rates ( Figure S2 ) and attenuated Ang-II-induced CH, as shown by substantial decreases in all CH markers ( Figure 2B and 2C Figure 2C ) and protein (3.83±0.77→1.29±0.29-fold; P<0.05; Figure 2D ) levels. The FHOD3 phosphorylation was decreased as well. Valsartan treatment decreased the phosphorylation on 1412S (3.07±0.85→0.86±0.13-fold; P<0.01) and 1416T (1.85±0.56→0.90±0.13-fold; P<0.01), but not 1406S (1.26±0.34→1.10±0.28-fold; P>0.05). In accordance, Ang-II-stimulated ROCK activity was significantly attenuated by Valsartan (208.6±27.4%→69.2±10.5%; P<0.01; Figure 2E ). These results suggest that Ang-II-induced FHOD3 upregulation and activation and ROCK activation were through AT1R.
Ang-II Activated and Upregulated Endogenous FHOD3 in NRCs
We next investigated the effects of Ang-II on FHOD3 phosphorylation in cultured NRCs. NRC cells were stimulated with Ang-II (100 nmol/L) for various times. Phosphorylation levels of 1406S, 1412S, and 1416T of FHOD3 were measured by Western blotting using corresponding phosphor-specific Figure 2 . Angiotensin II (Ang-II) upregulates and activates FHOD3 (formin homology 2 domain containing 3) and enhances ROCK (Rhoassociated coiled-coil containing protein kinase) activities in rat cardiac hypertrophy (CH) model. A, Before and after Ang-II infusion, the systolic (upper) and mean (lower) blood pressures (BPs) were measured and summarized from rats treated with saline (Sham; n=4), Ang-II (n=3) and Ang-II+Valsartan (n=3) groups. *P<0.05 vs 0 h within Ang-II group, vs Sham group at each time point, and vs Ang-II+Valsartan group at each time point. B, Representative images of gross hearts in cross-section (bar=1 cm) and hematoxylin eosin stainings (bar=25 μm) from Sham (n=6), Ang-II-infused (n=5), and Ang-II+Valsartan (n=5) rats harvested 4 wk after the infusion. The heart weight index (HWI) and the cross-sectional cardiomyocyte area were summarized in bar graphs below. C, β-myosin heavy chain (β-MHC), atrial natriuretic peptide (ANP), and FHOD3 RNA levels isolated from rat myocardium under each indicated condition were measured by real-time quantitative polymerase chain reaction (RT-qPCR) and normalized to GAPDH RNA as internal control. D, FHOD3 total protein and its phosphorylation levels of the 3 residues were measured from total protein extracts isolated from the rat left ventricle (LV) myocardium by Western blotting (WB). GAPDH expression was used for loading control. The expressions were quantified to GAPDH and shown as bar graph on the right. E, The ROCK activities in total extracts of the LV myocardium from treated rats were quantified by the ratio of phosphorylated myosin phosphatase 1 (MYPT1):total MYPT1. In B-E, *P<0.05 and #P<0.01 vs Sham. **P<0.05 and ##P<0.01 vs Ang-II.
antibodies. As shown in Figure 3A , increases in 1412S and 1416T were observed as early as 15 minutes after Ang-II addition, reaching peaks at 60 minutes post-treatment. As expected, no phosphorylation on 1406S was observed for the full 72-hour treatment, indicating that 1406S is not phosphorylated by kinases downstream of Ang-II signaling. In addition, an increase in FHOD3 expression was first detected 3 hours after Ang-II addition. It persistently increased throughout the time, with peak at 72-hour post-treatment.
FHOD3-AAA Abolished Ang-II-Induced Cardiomyocyte Hypertrophy in NRCs
The above results shown in Figure 3A suggest that Ang-II activates FHOD3 and increases its expression. To assess the functional role of FHOD3 activation in Ang-II signaling, we analyzed the 
Effects of the Phosphor-Mimetic and PhosphorResistant Mutant of FHOD3 on Cardiomyocyte Hypertrophy in NRCs
If activated FHOD3 is a key component of Ang-II-induced CH downstream of Ang-II, modulation of FHOD3 activation should be able to bypass the addition of Ang-II in cardiomyocyte hypertrophy. To address this, we again expressed GFP, GFP-FL-FHOD3-WT, -DDD, or -AAA mutants in NRCs via adenoviral transduction. Compared with nontransduced cardiomyocytes or the cells transduced with the control GFP virus, the expression of FHOD3-DDD, but not the WT, significantly increased myofibrillogenesis ( Figure 3C) 
Inhibition of ROCK Attenuates Ang-IIInduced FHOD3 Upregulation, Activation and Cardiomyocyte Hypertrophy
As shown above in Figure 2E , ROCK activities were increased in Ang-II-stimulated myocardium in vivo. To determine whether Ang-II-induced FHOD3 upregulation, activation, and cell hypertrophy in NRCs are through ROCK, we treated cultured NRCs with ROCK inhibitor Y27632 before the addition of Ang-II. Y27632 (10 μmol/L) treatment significantly attenuated Ang-II-induced increases in the phosphorylation levels of 1412S and 1416T ( Figure 4A ) and no detectable effect on the phosphorylation level of 1406S. Also, the cell sizes decreased with different concentrations of Y27632 (100 nmol/L-10 μmol/L) in concert with the same amount of Ang-II stimulation in a dose-dependent manner (1980±125 in 0 nmol/L; 1805±76 in 100 nmol/L; 1546±387 μm 2 in 10 μmol/L; Figure 4B ). The transcription of β-MHC (2.65±0.35→0.97±0.21-fold; Figure 4C ) and ANP (4.05±0.45→1.26±0.34-fold; Figure 4C ) and ROCK activities (150.2±25.2%→1.2±0.2%; P<0.01; Figure 4D ) were also decreased in similar fashion, indicating that Y27632 could attenuate Ang-II-induced cell hypertrophy. These results demonstrated that ROCK-mediated FHOD3 phosphorylation plays an important role in Ang-II-mediated cardiomyocyte hypertrophy.
In Vitro and Intracellular Phosphorylation of FHOD3 by ROCK Isoforms and Their Effects on SF Formation
Y27632 is a nonselective ROCK inhibitor. Previous study showed that ROCK1 could phosphorylate both FHOD1 and FHOD3 in vitro. 36, 37, 39, 44 As shown in Figure 5A , both ROCK1 and ROCK2 are detected in rat left ventricle with ROCK2 showing more enriched than ROCK1. Therefore, we next determined whether ROCK2 could phosphorylate FHOD3. We performed in vitro kinase assay using WT and the serial mutant forms of GST-1376-1439 as substrates for Ac-ROCK1 or Ac-ROCK2. As shown in Figure 5B , both kinases can phosphorylate WT and 3 mutant fragments with single Ala substitution. The amount of phosphorylated WT, AST, and SSA was highly increased by Ac-ROCK2, whereas both Ac-ROCK1 and Ac-ROCK2 showed no difference in phosphorylating SAT. When examining ROCK1/2 phosphorylation efficiency on 3 double-Ala substitution mutants and 1 triple-Ala substitution mutant, we observed that both Ac-ROCK1 and Ac-ROCK2 can phosphorylate ASA and AAT, but not SAA and AAA.
To further substantiate the above findings that ROCK2 possesses high phosphorylation activity on 1412S and 1416T, we further performed in vitro phosphorylation assay of WT and part of the mutant forms of GST-1376-1439 using FHOD3 phosphor-specific antibodies. For both 1412S and 1416T, Ac-ROCK2 demonstrated a stronger phosphorylation activity than Ac-ROCK1 ( Figure 5C ). Both kinases failed to phosphorylate 1406S and AAA. Taken together, our results demonstrated that both 1412S and 1416T are better substrates for ROCK2 than ROCK1.
Next, we seek to examine whether ROCK2-mediated FHOD3 phosphorylation is functional in SF formation. 36, 37, 39, 44 COS-1 cells were used as an in vitro model for comparison of the novel SF formation by the 2 kinases. Transfection of only CFP-CA-ROCK1, -ROCK2, or GFP-FL-FHOD3-WT did not induce SF formation ( Figure 5D ). As a positive control, transfection of GFP-FL-FHOD3-DDD alone stimulated massive SF formation. Cotransfection of CFP-CA-ROCK2 with GFP-FL-FHOD3-WT stimulated more SF formation than the cotransfection of -ROCK1 with -WT. In contrast, neither CFP-CA-ROCK1 nor -ROCK2 was able to stimulate SF formation when they cotransfected with GFP-FL-FHOD3-AAA mutant. These results indicated that ROCK2 activation of FHOD3 functions more potently in SF formation than that of ROCK1.
ROCK2 Is the Major Kinase That Is Responsible for Ang-II-Induced FHOD3 Activation and Cardiomyocyte Hypertrophy
Because both ROCK1 and ROCK2 can mediate FHOD3 activation, we wanted to determine which form was the major contributor to Ang-II-induced cardiomyocyte hypertrophy. Early results have shown the expression of both kinases in NRCs ( Figure 5A) . We reduced the expression of ROCK1 or ROCK2 by ROCK1-and ROCK2-specific shRNAs, respectively. As a result, the expression of ROCK1 or ROCK2 was stably reduced to 20%-25% by adenovirus-mediated shRNAs 24-72 hours post-transduction ( Figure 6A) . To determine the effect of ROCK1 and ROCK2 on Ang-II-induced cardiomyocyte hypertrophy, ROCK1 or ROCK2 knockdown NRCs were stimulated with Ang-II (100 nmol/L) for additional 48 hours after 24-hour transduction. Cell sizes, CH markers, and 
Discussion
In this study, we report for the first time that in cardiomyocytes (1) Ang-II induces the activation and upregulation of FHOD3 both in vivo and in vitro, (2) Valsartan and Y27632 attenuate Ang-II-induced FHOD3 activation/upregulation, (3) FHOD3 activation is a key step for Ang-II-induced myofibrillogenesis and cardiomyocyte hypertrophy, (4) FHOD3 is phosphorylated at 1412S and 1416T residues mainly by ROCK2 and weakly by ROCK1, and (5) ROCK2, but not ROCK1, knockdown in NRCs attenuates Ang-II-induced cell hypertrophy.
Among prohypertrophic agonists, including Ang-II, catecholamines, thrombin, endothelin-1, lysophosphatidic acid, and transforming growth factor-β, Ang-II is the most important factor for pressure overload-induced CH. [3] [4] [5] [6] [7] [8] [9] [10] Ang-II induces CH through several pathways, and Ang-II/AT1R→R hoA→ROCK 3, [18] [19] [20] [21] [22] [23] pathway is one of them. RhoA regulates myofibril formation through 2 downstream ROCK isoforms, ROCK1 and ROCK2. 18, 19 ROCK1 has been reported to play a critical role in mediating the effects of RhoA on myofibrillogenesis. 18, 19 Recent in vivo studies using ROCK inhibitors, Y27632 and fasudil, suggest an important role of ROCK in mediating CH. 50, 51 However, because of the nonselectivity of these compounds, it remains unclear whether there are functional differences between the 2 isoforms in mediating prohypertrophic effects. 52, 53 ROCK1 has been reported to phosphorylate FHOD3, as well as its paralog FHOD1 in nonmuscle cells. 36, 37 To date, no study has been conducted to compare the potency of ROCK1 and ROCK2 in phosphorylating FHOD3. In this study, we demonstrated that ROCK2 is the major kinase responsible for phosphorylating FHOD3 in cardiomyocytes and subsequent development of Ang-II-induced CH. The higher kinase potency of ROCK2 on FHOD3 may be the result of its higher expression level than ROCK1 in myocardium and its higher substrate selectivity for FHOD3. Consistent with our result, Julian and Olson 25 reported that the expression ratio of ROCK1:ROCK2 is about 1:3 in cardiomyocyte. In addition, Rikitake et al 54 reported that using ROCK1 heterozygous mice, Ang-II did not decrease CH progression. Instead, they observed a decrease in perivascular fibrosis induced by Ang-II. Zhang et al 55 showed that ROCK1 −/− mice still developed significant CH in response to aortic constriction. Shi et al 56 demonstrated that disruption of ROCK1 gene did not prevent the development of CH induced by cardiacspecific overexpression of Gαq. Okamoto et al 57 and Soliman et al 58 demonstrated that CH was attenuated in response to Ang-II/aortic constriction or high-fat diet-induced obesity in global heterozygous ROCK2 +/− mice. The above in vivo studies, together with previous studies using ROCK inhibitors, 50 ,51 supported our conclusion: in the development of Ang-II-induced CH, ROCK2 is the major mediator, whereas ROCK1 is dispensable. The mechanisms on how ROCK2 mediates CH remain largely unknown. Recently, Okamoto et al 57 reported that ROCK2-mediated CH is related in part to the upregulation of FHL2 (four-and-a-half LIM-only protein 2), a cardiac-specific transcriptional coactivator, leading to the inhibition of SRF and ERK expression. Either knockdown of FHL2 expression in ROCK2 +/− cardiomyocytes or placing ROCK2 +/− mice on FHL2 +/− background restored the hypertrophic response to Ang-II. In our study, we identified that FHOD3 is a novel substrate for ROCK2 and is also involved in mediating CH development. FHOD3-DDD mutant increases β-MHC and ANP expression, suggesting that the increase of myofibrillogenesis changes intracellular actin dynamics, that is, the ratio of F-actin:G-actin, which triggers the prohypertrophic genes expression. 59 However, we cannot exclude that other mechanisms underlying ROCK2-mediated CH may exist as well. ROCKs have been reported to target numerous downstream substrate proteins such as troponin, ezrin-radixin-moesin proteins, LIM kinase, PTEN (phosphatase and tensin homolog), and adducin. 59, 60 Many transcriptional factors, including GATA-4, NF-kB (nuclear factor kappa B), MEF-2 (myocyte enhancer factor 2), SRF (serum response factor), and EGR1 (early growth response 1), have been reported to induce CH. Among them, GATA-4 and SRF are known to be downstream targets of ROCK. 20, 57 In addition, ROCK2 may also participate in modulating pathways known to be critical for the development of CH, including ERK/GATA4, 20 reactive oxygen species/NF-kB, 32 Ca 2+ /calmodulin/calcineurin/NFAT (nuclear factor of activated T cell), 3 and mechanical integrin-focal adhesion kinase pathways. 3, 25 We also revealed the substrate selectivity of ROCK kinases to the 3 S/T residues highly conserved in the CT of FHOD homologues. Takeya et al 37 reported that ROCK1 could phosphorylate all 3 residues in FHOD1. For FHOD3, Iskratsch et al 44 recently used only His-tagged constitutively active ROCK1 to examine its phosphorylation on GST-CT-WT and Figure 6 . ROCK2 (Rho-associated coiled-coil containing protein kinase 2), but not ROCK1, is the major kinase responsible for angiotensin II (Ang-II)-induced FHOD3 (formin homology 2 domain containing 3) activation and cardiomyocyte hypertrophy. Neonatal rat cardiomyocyte (NRC) cells were transduced with adeno-shRNA against endogenous ROCK1 or ROCK2. A, Whole cell extracts were resolved by SDS-PAGE and immunoblotted with antibodies against ROCK1 or ROCK2 to confirm the knockdown of endogenous ROCK1 or ROCK2. n=3. *P<0.05. B, NRC cells with endogenous ROCK1 or ROCK2 knockdown were stimulated with Ang-II (100 nmol/L, 48 h). Cell surface areas (μm 2 ) were measured in 3 independent experiments with at least 100 α-actinin-stained cells being counted for each condition. β-myosin heavy chain (β-MHC) and atrial natriuretic peptide (ANP) mRNAs were evaluated by real-time quantitative polymerase chain reaction (RT-qPCR; n=3) and normalized to GAPDH mRNA. Bars=20 μm. *P<0.05 vs Blank. #P<0.01 vs Ang-II. C, FHOD3 protein and its phosphorylation levels were measured by Western blotting (WB) using extracts from NRCs under each condition as indicated. The results were quantified to GAPDH and shown as bar graphs on the right. *P<0.05 vs Blank. #P<0.01 vs Ang-II.
GST-CT-AAA fragments in vitro, followed by measuring the phosphorylation levels using general antiphosphor-S/T antibodies. They found a positive phosphorylation signal in GST-CT-WT and a negative signal in GST-CT-AAA, thus concluding that ROCK1 could directly phosphorylate all 3 residues in the CT of FHOD3 44 . In our study, we used multiple approaches and performed much more detailed mutational analysis either individually or in combination to determine that among the 3 S/T residues, both ROCK1 and ROCK2 can phosphorylate 1412S and 1416T with different potencies, but cannot phosphorylate 1406S. On the basis of quantification of the SF formation as functional readout in cultured COS-1 cells, the double phosphor-mimetic mutant form of FHOD3 at 1412S and 1416T (SDD) accounts for 75% of FHOD3 full activity, which could to be achieved by the ΔN or DDD. It is thus possible that under normal condition, the 1406S is not required to be phosphorylated by either ROCK1 or ROCK2 for FHOD3 activation. Consistent with this notion, we reported previously that 1131S in FHOD1, the corresponding residue to the 1406S in FHOD3, was a specific substrate for PKGI and was not involved in FHOD1 activation. 35 Our results showed that FHOD3-AAA mutant completely abolished all myofibrils in a dominant-negative fashion, whereas -DDD mutant significantly potentiated myofibrillogenesis and cell hypertrophy. These results suggested that a low level of FHOD3 phosphorylation is important for the maintenance of normal myofibril structure in cells. However, the NRCs transduced with FHOD3-AAA showed a much less myofibrils destruction when the cells were further stimulated with Ang-II. It is possible that Ang-II may activate a yet undiscovered pathway to induced myofibrillogenesis.
Apart from above-described phosphorylation level, FHOD3 expression level may be also important for the development of CH. Previous experimental studies showed that FHOD3 expression level determined myofibrillogenesis. Taniguchi et al 38 demonstrated that FHOD3 knockdown in cardiomyocytes had much decreased myofibrillogenesis and that cardiomyocytes with depletion of FHOD3 disrupted all of the sarcomere organization. FHOD3 −/− mice showed an embryonic lethality because premyofibrils failed to mature and myocardial development stalled. 43 Clinically, Iskratsch et al 39 reported that FHOD3 was downregulated in patients with DCM, both idiopathic and ischemic. Arimura et al 42 showed that a Y1249N variant in FHOD3 interfered with the myofibrillogenesis and caused DCM. Wooten et al 40 and Kan-o et al 41 reported that both the mRNA and protein of FHOD3 were upregulated in the myocardium of patients with HCM. These clinical reports indicated that FHOD3 expression levels were also important for myofibrillogenesis, which has been identified to be potentiated in HCM and attenuated in DCM. Considering the fact that the pathogenesis of HCM is similar to Ang-II-induced CH to a certain extent, it is consistent with what we found in our study that both FHOD3 activation and upregulation contributed to the increases in myofibrillogenesis and the subsequent CH. To further validate our findings in clinical cases, future experiments are needed to study not only FHOD3 expression levels but also its phosphorylation levels at the 3 S/T residues in patients with DCM and HCM, which are beyond the scope of current report.
There are several limitations in our study: (1) because our experiments were mainly performed in cultured cardiomyocytes, the ROCK2-mediated FHOD3 activation and its effect on CH need to be further verified in vivo in ROCK1 null mice, [54] [55] [56] in ROCK2 null mice, 57, 58 and in cardiac-specific transgenic mice of phosphor-mimetic mutant form of FHOD3 (SDD); (2) further molecular and cellular studies are needed to address the mechanism on how activated FHOD3 induces hypertrophic gene expression and cardiomyocyte hypertrophy; (3) among FHOD3's 3 phosphorylable residues (1406S, 1412S, and 1416T), the physiological function of 1406S phosphorylation by PKG also need to be addressed; and (4) finally, our conclusion may only be applied to cardiomyocytes. Cautions should be taken when explaining the function of FHOD1 in cells other than cardiomyocytes. We have previously reported that in smooth muscle cells, the expression of FHOD1 35 resulted in opposite phenotype. In smooth muscle cells, ROCK2 is mainly responsible for upregulation of the contractility, whereas ROCK1 is responsible for increased synthesis of SF and enlarged cell size. 31 
Perspectives
It has been unclear about the in vivo physiological/pathological activator for FHOD3 in cardiomyocytes. Our results identified for the first time that Ang-II, the most important prohypertrophic growth factor for CH, is the upstream activator and upregulator of FHOD3 in vivo. Therefore, our results unravel the mechanism of the Ang-II signaling in cardiomyocytes that is mediated through ROCK2/FHOD3. Ang-II potentiates myofibrillogenesis and induces CH through ROCK2-mediated phosphorylation of FHOD3 at 1412S and 1416T. Taken together, our study identifies a novel pathway, Ang-II/AT1R→RhoA→ROCK2→FHOD3→myofib rillogenesis, that plays a physiological role in myofibrillogenesis and pathophysiological role in the development of CH. Further studies are needed to address the question on whether ROCK2-mediated FHOD3 phosphorylation is the final common pathway for the pathogenesis of CH induced by other prohypertrophic agonists, such as endothelin-1 and catecholamines.
